B Motheral

Summary

Affiliation: Express Scripts
Country: USA

Publications

  1. ncbi Effect of a three-tier prescription copay on pharmaceutical and other medical utilization
    B Motheral
    Express Scripts, Inc, Maryland Heights, Missouri 63043, USA
    Med Care 39:1293-304. 2001
  2. ncbi Financial consequences of drug benefit plans
    Brenda Motheral
    JAMA 289:423-4; author reply 424. 2003
  3. ncbi A checklist for retrospective database studies--report of the ISPOR Task Force on Retrospective Databases
    Brenda Motheral
    Express Scripts, Maryland Heights, MO 63043, USA
    Value Health 6:90-7. 2003
  4. ncbi Prescribing COX-2s for patients new to cyclo-oxygenase inhibition therapy
    Emily R Cox
    Office of Research and Planning, Express Scripts, Inc, 13900 Riverport Drive, Maryland Heights, MO 63043, USA
    Am J Manag Care 9:735-42. 2003
  5. ncbi Verification of a decision analytic model assumption using real-world practice data: implications for the cost effectiveness of cyclo-oxygenase 2 inhibitors (COX-2s)
    Emily R Cox
    Office of Research and Planning, Express Scripts, Inc, 13900 Riverport Drive, Maryland Heights, MO 63043, USA
    Am J Manag Care 9:785-94. 2003
  6. ncbi Conclusions of cost-effectiveness for an asthma intervention might not be warranted
    Thomas Delate
    J Allergy Clin Immunol 111:654-5; author reply 655-6. 2003
  7. ncbi Assessing the value of the Quality of Health Economic Studies (QHES)
    Brenda Motheral
    J Manag Care Pharm 9:86-7. 2003
  8. ncbi Outcomes research in health care: simulations to drive cost conclusions
    Raulo Frear
    Express Scripts, Inc, Maryland Heights, MO 55439-0842, USA
    Value Health 7:11-2. 2004

Detail Information

Publications8

  1. ncbi Effect of a three-tier prescription copay on pharmaceutical and other medical utilization
    B Motheral
    Express Scripts, Inc, Maryland Heights, Missouri 63043, USA
    Med Care 39:1293-304. 2001
    ..In response to rising prescription drug costs, plan sponsors are increasingly implementing three-tiered pharmacy benefits...
  2. ncbi Financial consequences of drug benefit plans
    Brenda Motheral
    JAMA 289:423-4; author reply 424. 2003
  3. ncbi A checklist for retrospective database studies--report of the ISPOR Task Force on Retrospective Databases
    Brenda Motheral
    Express Scripts, Maryland Heights, MO 63043, USA
    Value Health 6:90-7. 2003
    ..However, retrospective databases pose a series of methodological challenges, some of which are unique to this data source...
  4. ncbi Prescribing COX-2s for patients new to cyclo-oxygenase inhibition therapy
    Emily R Cox
    Office of Research and Planning, Express Scripts, Inc, 13900 Riverport Drive, Maryland Heights, MO 63043, USA
    Am J Manag Care 9:735-42. 2003
    ..To profile the pattern of cyclo-oxygenase 2 inhibitor (COX-2) use, including length of therapy, medical conditions treated, and gastrointestinal (GI) risk profile of users...
  5. ncbi Verification of a decision analytic model assumption using real-world practice data: implications for the cost effectiveness of cyclo-oxygenase 2 inhibitors (COX-2s)
    Emily R Cox
    Office of Research and Planning, Express Scripts, Inc, 13900 Riverport Drive, Maryland Heights, MO 63043, USA
    Am J Manag Care 9:785-94. 2003
    ..To verify the gastroprotective agent (GPA) rate assumption used in cost-effectiveness models for cyclo-oxygenase 2 inhibitors (COX-2s) and to re-estimate model outcomes using GPA rates from actual practice...
  6. ncbi Conclusions of cost-effectiveness for an asthma intervention might not be warranted
    Thomas Delate
    J Allergy Clin Immunol 111:654-5; author reply 655-6. 2003
  7. ncbi Assessing the value of the Quality of Health Economic Studies (QHES)
    Brenda Motheral
    J Manag Care Pharm 9:86-7. 2003
  8. ncbi Outcomes research in health care: simulations to drive cost conclusions
    Raulo Frear
    Express Scripts, Inc, Maryland Heights, MO 55439-0842, USA
    Value Health 7:11-2. 2004